Drugs / OP-3136
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06784193 | Dec 2024 → May 2027 expected | castration-resistant prostate carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma, progesterone-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OP-3136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06784193 ↗ |
| Action | Inhibit | “Selective inhibitor of HAT enzymes KAT6A and KAT6B” NCT06784193 ↗ |
| Route | Oral | “administered orally once daily” NCT06784193 ↗ |
| Target | KAT6A | “Selective inhibitor of HAT enzymes KAT6A and KAT6B” NCT06784193 ↗ |
| Target | KAT6B | “Selective inhibitor of HAT enzymes KAT6A and KAT6B” NCT06784193 ↗ |